Expression of Melan-A in Depigmented Skin of Vitiligo Patients

Background: Vitiligo is an acquired and commonly found pigmentation disorder characterized by milky-white patches on the skin, hair, and mucosa due to melanocyte damage. The cause of vitiligo is still unclear. A study proves that cell-mediated immunity plays a role in the pathogenesis of vitiligo. Melan-A is a melanoma-related antigen that is recognized by autologous cytotoxic T cells and one of the critical markers for detecting melanocytes. Objective : To evaluate the expression of Melan-A in depigmented lesions of vitiligo patients. Methods: A descriptive study aimed to describe the expression of Melan-A in the depigmented skin of vitiligo patients at the Dermatovenerology Outpatient Clinic Cosmetic Division of Academic General Hospital Dr. Soetomo Surabaya. Eleven study subjects were selected through a sequence of selection. Results: Melan-A expression in the depigmented skin of vitiligo patients was lower than the average. This result was found in 6 (54.55%) out of 11 patients. Conclusion: Melan-A expressions on depigmented skins of vitiligo patients are generally below the average value; therefore, adequate intervention is needed to increase the Melan-A expression.

[1]  B. Eberlein,et al.  Therapeutic management of vitiligo , 2018, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[2]  Y. Hasija,et al.  Exploring vitiligo susceptibility and management: a brief review , 2018, Biomedical Dermatology.

[3]  B. Selvan,et al.  Pattern of Repigmentation in the Treatment of Vitiligo Vulgaris with NBUVB Therapy , 2018 .

[4]  A. Bishnoi,et al.  Clinical and Molecular Aspects of Vitiligo Treatments , 2018, International journal of molecular sciences.

[5]  N. Elbuluk,et al.  Advances in Vitiligo: An Update on Medical and Surgical Treatments. , 2017, The Journal of clinical and aesthetic dermatology.

[6]  M. A. E. Kholy IMMUNOHISTOCHEMICAL EXPRESSION OF MELAN A AND ITS RELATION TO EXPRESSION OF CXCR3 IN VITILIGO LESIONS , 2016 .

[7]  A. Kubanov,et al.  Immunohistochemical analysis of melanocyte content in different zones of vitiligo lesions using the Melan-A marker. , 2016, Acta dermatovenerologica Alpina, Pannonica, et Adriatica.

[8]  Liliane Machado do Nascimento,et al.  Vitiligo - Part 1 , 2014, Anais brasileiros de dermatologia.

[9]  D. Parsad A New Era of Vitiligo Research and Treatment , 2013, Journal of cutaneous and aesthetic surgery.

[10]  Takashi Hashimoto,et al.  Disease Severity Indexes and Treatment Evaluation Criteria in Vitiligo , 2011, Dermatology research and practice.

[11]  K. Sharquie,et al.  Inflammatory Changes in Vitiligo: Stage I and II Depigmentation , 2004, The American Journal of dermatopathology.

[12]  D. Gawkrodger,et al.  Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1 , 2002, Clinical and experimental immunology.

[13]  A. Abdel-rahman,et al.  Evaluation of the Role of Apoptosis in Vitiligo: Immunohistochemical Expression of P53, Bcl-2 and MART-1 Antigens , 2002 .

[14]  J. Weening,et al.  Autoimmune Melanocyte Destruction in Vitiligo , 2001, Laboratory Investigation.